Literature DB >> 28507124

Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase.

Pan F Chan1, Thomas Germe2, Benjamin D Bax3, Jianzhong Huang4, Reema K Thalji4, Eric Bacqué5, Anna Checchia6, Dongzhao Chen4, Haifeng Cui4, Xiao Ding4, Karen Ingraham4, Lynn McCloskey4, Kaushik Raha4, Velupillai Srikannathasan3, Anthony Maxwell2, Robert A Stavenger1.   

Abstract

A paucity of novel acting antibacterials is in development to treat the rising threat of antimicrobial resistance, particularly in Gram-negative hospital pathogens, which has led to renewed efforts in antibiotic drug discovery. Fluoroquinolones are broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA-cleavage complexes, but their clinical utility has been compromised by resistance. We have identified a class of antibacterial thiophenes that target DNA gyrase with a unique mechanism of action and have activity against a range of bacterial pathogens, including strains resistant to fluoroquinolones. Although fluoroquinolones stabilize double-stranded DNA breaks, the antibacterial thiophenes stabilize gyrase-mediated DNA-cleavage complexes in either one DNA strand or both DNA strands. X-ray crystallography of DNA gyrase-DNA complexes shows the compounds binding to a protein pocket between the winged helix domain and topoisomerase-primase domain, remote from the DNA. Mutations of conserved residues around this pocket affect activity of the thiophene inhibitors, consistent with allosteric inhibition of DNA gyrase. This druggable pocket provides potentially complementary opportunities for targeting bacterial topoisomerases for antibiotic development.

Entities:  

Keywords:  antibiotic; drug discovery; topoisomerase

Mesh:

Substances:

Year:  2017        PMID: 28507124      PMCID: PMC5465892          DOI: 10.1073/pnas.1700721114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Macromolecular synthesis and membrane perturbation assays for mechanisms of action studies of antimicrobial agents.

Authors:  Amy Cotsonas King; Liping Wu
Journal:  Curr Protoc Pharmacol       Date:  2009-12

Review 2.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

3.  Structural basis for gate-DNA recognition and bending by type IIA topoisomerases.

Authors:  Ken C Dong; James M Berger
Journal:  Nature       Date:  2007-12-20       Impact factor: 49.962

4.  Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

Authors:  Timothy J Miles; Alan J Hennessy; Ben Bax; Gerald Brooks; Barry S Brown; Pamela Brown; Nathalie Cailleau; Dongzhao Chen; Steven Dabbs; David T Davies; Joel M Esken; Ilaria Giordano; Jennifer L Hoover; Jianzhong Huang; Graham E Jones; Senthill K Kusalakumari Sukmar; Claus Spitzfaden; Roger E Markwell; Elisabeth A Minthorn; Steve Rittenhouse; Michael N Gwynn; Neil D Pearson
Journal:  Bioorg Med Chem Lett       Date:  2013-07-17       Impact factor: 2.823

Review 5.  ESKAPEing the labyrinth of antibacterial discovery.

Authors:  Ruben Tommasi; Dean G Brown; Grant K Walkup; John I Manchester; Alita A Miller
Journal:  Nat Rev Drug Discov       Date:  2015-07-03       Impact factor: 84.694

6.  In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens.

Authors:  D J Biedenbach; S K Bouchillon; M Hackel; L A Miller; N E Scangarella-Oman; C Jakielaszek; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

Review 7.  Mechanisms of drug resistance: quinolone resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.

Authors:  Katie J Aldred; Tim R Blower; Robert J Kerns; James M Berger; Neil Osheroff
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-20       Impact factor: 11.205

10.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13
View more
  15 in total

1.  Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations.

Authors:  Petra Szili; Gábor Draskovits; Tamás Révész; Ferenc Bogár; Dávid Balogh; Tamás Martinek; Lejla Daruka; Réka Spohn; Bálint Márk Vásárhelyi; Márton Czikkely; Bálint Kintses; Gábor Grézal; Györgyi Ferenc; Csaba Pál; Ákos Nyerges
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 2.  Topoisomerases as anticancer targets.

Authors:  Justine L Delgado; Chao-Ming Hsieh; Nei-Li Chan; Hiroshi Hiasa
Journal:  Biochem J       Date:  2018-01-23       Impact factor: 3.857

3.  Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration.

Authors:  Gan Luan; Yuzhi Hong; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.

Authors:  Elizabeth G Gibson; Ben Bax; Pan F Chan; Neil Osheroff
Journal:  ACS Infect Dis       Date:  2019-02-28       Impact factor: 5.084

5.  Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosis.

Authors:  Yu Imai; Glenn Hauk; Jeffrey Quigley; Libang Liang; Sangkeun Son; Meghan Ghiglieri; Michael F Gates; Madeleine Morrissette; Negar Shahsavari; Samantha Niles; Donna Baldisseri; Chandrashekhar Honrao; Xiaoyu Ma; Jason J Guo; James M Berger; Kim Lewis
Journal:  Nat Chem Biol       Date:  2022-08-22       Impact factor: 16.174

6.  De novo design of type II topoisomerase inhibitors as potential antimicrobial agents targeting a novel binding region.

Authors:  Kyle M Orritt; Lipeng Feng; Juliette F Newell; Jack N Sutton; Scott Grossman; Thomas Germe; Lauren R Abbott; Holly L Jackson; Benjamin K L Bury; Anthony Maxwell; Martin J McPhillie; Colin W G Fishwick
Journal:  RSC Med Chem       Date:  2022-06-16

7.  Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.

Authors:  Elizabeth G Gibson; Tim R Blower; Monica Cacho; Ben Bax; James M Berger; Neil Osheroff
Journal:  ACS Infect Dis       Date:  2018-05-17       Impact factor: 5.084

8.  Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.

Authors:  Sebastian Franco-Ulloa; Giuseppina La Sala; Gian Pietro Miscione; Marco De Vivo
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

9.  A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.

Authors:  Thomas Germe; Judit Vörös; Frederic Jeannot; Thomas Taillier; Robert A Stavenger; Eric Bacqué; Anthony Maxwell; Benjamin D Bax
Journal:  Nucleic Acids Res       Date:  2018-05-04       Impact factor: 16.971

10.  New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.

Authors:  Martina Durcik; Denise Lovison; Žiga Skok; Cristina Durante Cruz; Päivi Tammela; Tihomir Tomašič; Davide Benedetto Tiz; Gábor Draskovits; Ákos Nyerges; Csaba Pál; Janez Ilaš; Lucija Peterlin Mašič; Danijel Kikelj; Nace Zidar
Journal:  Eur J Med Chem       Date:  2018-05-10       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.